The Science Journal of the Lander College of Arts and Sciences
Abstract
Melanoma is an increasingly prevalent skin cancer with a high mortality rate in advanced stages. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have transformed treatment outcomes for many patients, but a substantial proportion of melanomas still show primary or acquired resistance. One of the main factors shaping the response to PD-1 blockade is the presence of cytotoxic CD8⁺T cells within the tumor microenvironment. This paper reviews evidence that melanoma can evade immune detection by downregulating major histocompatibility complex class I (MHC-I) expression, which limits effective T-cell infiltration. The three studies discussed examine how MHC-I loss relates to T-cell exclusion, transcriptional reprogramming, and genomic escape mechanisms. Together, these findings highlight the importance of antigen presentation in immunotherapy and support therapeutic strategies aimed at restoring tumor visibility to the immune system.
Recommended Citation
Lerner, D. (2026). Resistance to Immunotherapy in Melanoma Patients. The Science Journal of the Lander College of Arts and Sciences, 19(2), 101-104. Retrieved from https://touroscholar.touro.edu/sjlcas/vol19/iss2/13
Request Accessible Format Need this file in a format that works better with assistive technology? Submit a request.
